Valneva Advances New Vaccines Agenda With Top-Line Phase III Chikungunya Data
Final Results Within The Next Six Months
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.
